Our Recommendations
- Recommendations on the delivery of health services for the prevention and care of sexually transmitted infections (2025)
- Outcomes of lenacapavir administration during pregnancy (2025)
- Mathematical modelling of lenacapavir: landscaping review on impact and cost–effectiveness (2025)
- Should HIV testing services with rapid diagnostic tests and/or self-tests be used for initiation or continuation of injectable long-acting PrEP? (2025)
- Systematic review of values and preferences for lenacapavir as pre-exposure prophylaxis and other forms of long-acting injectable PrEP (2025)
New Publications
- Recommendations on the delivery of health services for the prevention and care of sexually transmitted infections (2025)
- Outcomes of lenacapavir administration during pregnancy (2025)
- Lenacapavir-associated drug resistance: implications for scaling up long-acting PrEP (2025)
- Mathematical modelling of lenacapavir: landscaping review on impact and cost–effectiveness (2025)
- Should HIV testing services with rapid diagnostic tests and/or self-tests be used for initiation or continuation of injectable long-acting PrEP? (2025)
Filter
359
Featured
Recommendations
23
New Publications
43
Language
Document type
Guidelines
126
No document type
121
Studies & Reports
65
Fact sheets
22
Infographics
9
Manuals
5
Situation Updates
3
Training Material
2
Resource Platforms
2
Strategic & Response Plan
2
Brochures
1
Online Courses
1
Countries / Regions
Malawi
8
Global
8
Latin America and the Carribbean
7
South Africa
7
Africa
5
East and Southern Africa
5
Uganda
4
Asia
3
South–East Asia Region
3
Western and Central Europe
3
Kenya
2
Lesotho
2
Zambia
2
Nepal
1
El Salvador
1
Syria
1
Laos
1
Afghanistan
1
Zimbabwe
1
Philippines
1
Mozambique
1
USA
1
Cambodia
1
Guinea-Bissau
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
Western Pacific Region
1
North America
1
Jamaica
1
Argentina
1
Bangladesh
1
Vietnam
1
Brazil
1
Sri Lanka
1
Russia
1
Yemen
1
Angola
1
Bhutan
1
India
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
53
Countries
30
Women & Child Health
8
Pharmacy & Technologies
3
Public Health
2
Capacity Building
1
Key Resources
1
Breakthrough innovations have come to light that have proved to be more than 95% effective in preventing HIV infection with injections just twice a year. Once a year might even be possible. They could also be key for 40 million people living with HIV around the world who need better options for trea...
A historic funding crisis is threatening to unravel decades of progress unless countries can make radical shifts to HIV programming and funding. The report highlights the impact that the sudden, large-scale funding cuts from international donors are having on countries most affected by HIV. Yet it a...
2025 Global AIDS Update — AIDS, Crisis and the Power to Transform. Excecutive Summary
recommended
New
A historic funding crisis is threatening to unravel decades of progress unless countries can make radical shifts to HIV programming and funding. The report highlights the impact that the sudden, large-scale funding cuts from international donors are having on countries most affected by HIV. Yet it a...
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...
Safety and efficacy of long-acting injectable lenacapavir as pre-exposure prophylaxis to reduce the risk of HIV acquisition: a systematic review
recommended
New
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Systematic review of values and preferences for lenacapavir as pre-exposure prophylaxis and other forms of long-acting injectable PrEP
recommended
New
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex C
Should HIV testing services with rapid diagnostic tests and/or self-tests be used for initiation or continuation of injectable long-acting PrEP?
recommended
New
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex D
Mathematical modelling of lenacapavir: landscaping review on impact and cost–effectiveness
recommended
New
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex E
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex F
Outcomes of lenacapavir administration during pregnancy
recommended
New
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex G Abstract
Recommendations on the delivery of health services for the prevention and care of sexually transmitted infections
recommended
New
These guidelines promote the delivery of people-centred health services for STIs by providing evidence-based recommendations related to decentralization, integration, task sharing and digital health. These recommendations complement existing WHO guidelines for STI testing, treatment and management, ...
Cervical cancer is a disease of the female reproductive tract caused primarily by oncogenic types of human papillomavirus
(HPV). In 2020, it was the fourth most common cancer among women worldwide, with an estimated 604 000 new cases and 342 000 deaths
HIV testing programmes need to ensure that all clients who test for HIV are provided with correct diagnoses. The accuracy of HIV testing is critical to prevent misdiagnosis, as the consequences of giving an incorrect test result can be serious for clients, HIV testing services, HIV programmes and pu...
Advanced HIV disease (defined in persons living with HIV with a CD4 cell count of <200cells/mm3 or presenting with a WHO Stage 3/4 AIDS-defining illness) poses a challenge to many countries globally and is responsible for significant mortality and morbidity among people living with HIV. In 2017, WHO...
Despite the development of point-of-care diagnostic tests for syphilis, chlamydia, gonorrhoea, and trichomoniasis, none comply with all WHO criteria. This analysis overviews landscape analyses of point-of-care diagnostic technologies for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vagi...
Men experience increased risk of morbidity and mortality across all ten major contributors to poor health and continue to lag behind women regarding HIV services and other health outcomes. Globally, men now account for the majority of new HIV infections. In 2022, only 72% of men living with HIV (age...
Pregnancy and childbirth during adolescence profoundly affects the lives of millions of girls worldwide, and is a leading cause of maternal mortality and morbidity, and infant and child mortality. Every year, an estimated 21 million girls aged 15–19 years old in low- and middle-income countries be...
Epidemiology
Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or...
This updated manual provides a basic understanding of the principles of laboratory and point-of-care (POC) testing in the context of screening and diagnostic approaches, as well as antimicrobial susceptibility testing, as components of sexually transmitted infections (STIs) control. As with previous...
